Prophylactic low-dose paracetamol administration associated with lowered rate of patent ductus arteriosus in preterm infants - Impact on outcome and pain perception.


Journal

Pediatrics and neonatology
ISSN: 2212-1692
Titre abrégé: Pediatr Neonatol
Pays: Singapore
ID NLM: 101484755

Informations de publication

Date de publication:
02 2020
Historique:
received: 16 12 2018
revised: 07 06 2019
accepted: 28 06 2019
pubmed: 28 7 2019
medline: 21 8 2020
entrez: 27 7 2019
Statut: ppublish

Résumé

To determine the rate of patent ductus arteriosus after prophylactic low-dose paracetamol administration, the impact on outcome parameters, possible treatment side-effects and the influence on pain perception. We report retrospective single-centre outcome data of premature infants ≤ 32 weeks of gestation (n = 476). The intervention group received intravenous paracetamol, the control group obtained no preventive therapy. Ductal closure rate and outcome parameters were compared between the two groups. Adverse effects were determined by laboratory parameters. For the assessment of pain the Bernese Pain Scale for Neonates was used. The rate of patent ductus arteriosus was significantly lower in the paracetamol-treated group compared to the control group (13.6% vs. 38.2%, p < 0.001). With regard to secondary outcome parameters, severe and moderate bronchopulmonary dysplasia (2.7% vs. 7.4%, p = 0.023), severe retinopathy of prematurity (0% vs. 4.4%, p = 0.002) and late onset sepsis (2.7% vs. 8.3%, p = 0.009) were significantly less frequent in the paracetamol group. Except for a 1.5-fold increased risk for hyperbilirubinemia (86.0% vs. 77.6%, p = 0.035) in the paracetamol group following treatment, no significant differences in laboratory parameters were found. Relating to pain, the administration of Glucose 33% was significantly more often necessary in the control group compared to the paracetamol-treated group (mean 13.48 vs. 8.71, p < 0.001), just as the need for additional treatment with systemic analgesics, which was more frequent in the control group (mean 0.72 vs. 0.57, p = 0.361). In our study we were able to show a significantly lower rate of patent ductus arteriosus after prophylactic paracetamol administration without serious adverse effect, but a beneficial influence of this regime on the patient's pain perception.

Sections du résumé

BACKGROUND
To determine the rate of patent ductus arteriosus after prophylactic low-dose paracetamol administration, the impact on outcome parameters, possible treatment side-effects and the influence on pain perception.
METHODS
We report retrospective single-centre outcome data of premature infants ≤ 32 weeks of gestation (n = 476). The intervention group received intravenous paracetamol, the control group obtained no preventive therapy. Ductal closure rate and outcome parameters were compared between the two groups. Adverse effects were determined by laboratory parameters. For the assessment of pain the Bernese Pain Scale for Neonates was used.
RESULTS
The rate of patent ductus arteriosus was significantly lower in the paracetamol-treated group compared to the control group (13.6% vs. 38.2%, p < 0.001). With regard to secondary outcome parameters, severe and moderate bronchopulmonary dysplasia (2.7% vs. 7.4%, p = 0.023), severe retinopathy of prematurity (0% vs. 4.4%, p = 0.002) and late onset sepsis (2.7% vs. 8.3%, p = 0.009) were significantly less frequent in the paracetamol group. Except for a 1.5-fold increased risk for hyperbilirubinemia (86.0% vs. 77.6%, p = 0.035) in the paracetamol group following treatment, no significant differences in laboratory parameters were found. Relating to pain, the administration of Glucose 33% was significantly more often necessary in the control group compared to the paracetamol-treated group (mean 13.48 vs. 8.71, p < 0.001), just as the need for additional treatment with systemic analgesics, which was more frequent in the control group (mean 0.72 vs. 0.57, p = 0.361).
CONCLUSION
In our study we were able to show a significantly lower rate of patent ductus arteriosus after prophylactic paracetamol administration without serious adverse effect, but a beneficial influence of this regime on the patient's pain perception.

Identifiants

pubmed: 31345732
pii: S1875-9572(18)30780-0
doi: 10.1016/j.pedneo.2019.06.011
pii:
doi:

Substances chimiques

Acetaminophen 362O9ITL9D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

84-91

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Michaela Höck (M)

Medical University of Innsbruck, Department of Paediatrics II, Division of Neonatology, Austria.

Barbara Brunner (B)

Medical University of Innsbruck, Department of Paediatrics II, Division of Neonatology, Austria.

Vera Rier (V)

Medical University of Innsbruck, Department of Paediatrics II, Division of Neonatology, Austria.

Stefanie Thöni (S)

Medical University of Innsbruck, Department of Paediatrics II, Division of Neonatology, Austria.

Rudolf Trawöger (R)

Medical University of Innsbruck, Department of Paediatrics II, Division of Neonatology, Austria.

Ralf Geiger (R)

Medical University of Innsbruck, Department of Paediatrics III, Division of Cardiology, Pulmonology, Allergology and Cystic Fibrosis, Austria.

Elisabeth Schermer (E)

Medical University of Innsbruck, Department of Paediatrics III, Division of Cardiology, Pulmonology, Allergology and Cystic Fibrosis, Austria.

Thomas Karall (T)

Medical University of Innsbruck, Department of Paediatrics III, Division of Cardiology, Pulmonology, Allergology and Cystic Fibrosis, Austria.

Ursula Kiechl-Kohlendorfer (U)

Medical University of Innsbruck, Department of Paediatrics II, Division of Neonatology, Austria. Electronic address: Ursula.Kohendorfer@i-med.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH